Also trades as: BHC.TO (TSX) · $vol 4M
BHC NYSE
Bausch Health Companies Inc.
1W: -1.7%
1M: +9.4%
3M: +34.8%
YTD: -12.5%
1Y: +1.8%
3Y: -13.8%
5Y: -77.8%
$6.31
-0.04 (-0.71%)
Pre-Market: $6.29 (-0.01, -0.24%)
Weekly Expected Move ±4.4%
$6
$6
$6
$7
$7
Credit Risk of going bust: higher than 87% of companies Debt: 89.8% of company value Bonds: $300.9M held by 287 funds, 1254 bp over Treasuries → details ▾
If the stock fell to about $1.86 (down 71%), Bausch Health Companies Inc. would be worth roughly what it owes.
Total debt $20.78B against a stock market value of $2.36B.
Distance to default 1.94 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $10.80B (short-term plus half of long-term), stock volatility 54.1%; Altman Z'' -0.73. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Total debt $20.78B against a stock market value of $2.36B.
Distance to default 1.94 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $10.80B (short-term plus half of long-term), stock volatility 54.1%; Altman Z'' -0.73. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships5
As Filer
counterparties named
2
As Counterparty
mentioned by others
2
Rel. Types
2022-06-23
Earliest Filing
2024-01-16
Latest Filing
target: 3
acquirer: 2
Counterparties (Filed by BHC)
5 relationshipsCompanies named in BHC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Novartis | NVSEF | target | Seller of XIIDRA and certain other ophthalmology assets acquired by Bausch + Lomb | 2023-09-29 | View |
| Novartis Pharma AG | NVSEF | target | Seller of XIIDRA and ophthalmology assets in a $1.75 billion acquisition | 2023-07-07 | View |
| Novartis Finance Corporation | NVSEF | target | Co-seller with Novartis Pharma AG in the asset purchase agreement | 2023-07-07 | View |
| Bausch + Lomb Corporation | BHC | acquirer | Parent company of the acquiring subsidiary Bausch + Lomb Ireland Limited | 2023-07-07 | View |
| Bausch + Lomb Ireland Limited | BLCO | acquirer | Wholly owned subsidiary of Bausch + Lomb Corporation acquiring ophthalmology assets | 2023-07-07 | View |
Mentioned As Counterparty
2 mentionsOther companies that named BHC in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-29 | Earnings Release; Exhibits | View | |
| 2026-07-01 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-05-19 | Shareholder Vote | View | |
| 2026-04-29 | Earnings Release; Exhibits | View | |
| 2026-03-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-18 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-23 | Regulation FD Disclosure | View | |
| 2026-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2026-01-02 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Other Events; Fin | Agreement | View |
| 2025-12-29 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-12-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-09 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-09-11 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-15 | Termination of Material Definitive Agreement; Departure/Election of Directors; Appointment of Office | View | |
| 2025-07-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-29 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR